Review article · 2012 · Open access

Key Anticipated Regulatory Issues for Clinical Use of Human Induced Pluripotent Stem Cells

Paul S. Knoepfler

Regenerative Medicine, 7(5), 713–720 · Published 1 September 2012 · DOI 10.2217/rme.12.51

Open full textView at the publisherCite this paper

In brief

“Key Anticipated Regulatory Issues for Clinical Use of Human Induced Pluripotent Stem Cells” is a 2012 review article by Paul S. Knoepfler, published in Regenerative Medicine. OpenAlex counts 26 citations as of 21 November 2026. It is open access: the full text is free to read at Europe PMC (PubMed Central).

Citations
26
Most cited in
2013 (5)
Field-weighted impact
0.21
References
51
Authors
1

Abstract

The production of human induced pluripotent stem cells (hiPSCs) has greatly expanded the realm of possible stem cell-based regenerative medicine therapies and has particularly exciting potential for autologous therapies. However, future therapies based on hiPSCs will first have to address not only similar regulatory issues as those facing human embryonic stem cells with the US FDA and international regulatory agencies, but also hiPSCs have raised unique concerns as well. While the first possible clinical use of hiPSCs remains down the road, as a field it would be wise for us to anticipate potential roadblocks and begin formulating solutions. In this article, I discuss the potential regulatory issues facing hiPSCs and propose some potential changes in the direction of the field in response.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Knoepfler, P. S. (2012). Key Anticipated Regulatory Issues for Clinical Use of Human Induced Pluripotent Stem Cells. Regenerative Medicine, 7(5), 713–720. https://doi.org/10.2217/rme.12.51

MLA 9

Knoepfler, Paul S. “Key Anticipated Regulatory Issues for Clinical Use of Human Induced Pluripotent Stem Cells.” Regenerative Medicine, vol. 7, no. 5, 2012, pp. 713–720. https://doi.org/10.2217/rme.12.51.

Chicago

Knoepfler, Paul S. 2012. “Key Anticipated Regulatory Issues for Clinical Use of Human Induced Pluripotent Stem Cells.” Regenerative Medicine 7 (5): 713–720. https://doi.org/10.2217/rme.12.51.

Harvard

Knoepfler, P. S. (2012) ‘Key Anticipated Regulatory Issues for Clinical Use of Human Induced Pluripotent Stem Cells’, Regenerative Medicine, 7(5), pp. 713–720. doi:10.2217/rme.12.51.

IEEE

P. S. Knoepfler, “Key Anticipated Regulatory Issues for Clinical Use of Human Induced Pluripotent Stem Cells,” Regenerative Medicine, vol. 7, no. 5, pp. 713–720, 2012, doi: 10.2217/rme.12.51.

BibTeX

@article{knoepfler2012anticipated,
  title     = {{Key Anticipated Regulatory Issues for Clinical Use of Human Induced Pluripotent Stem Cells}},
  author    = {Knoepfler, Paul S.},
  journal   = {Regenerative Medicine},
  year      = {2012},
  volume    = {7},
  number    = {5},
  pages     = {713--720},
  doi       = {10.2217/rme.12.51},
  url       = {https://doi.org/10.2217/rme.12.51}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201355
201433
201622
201755
201922
202111
202333
202422
202522
202611

Its field-weighted citation impact is 0.21: it has been cited 0.21 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research

  • human induced pluripotent stem cells
  • stem cell regulation
  • clinical translation
  • autologous cell therapy
  • FDA regulation
  • regulatory challenges
  • stem cell therapy

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Knoepfler, P. S. (2012). Key Anticipated Regulatory Issues for Clinical Use of Human Induced Pluripotent Stem Cells. Regenerative Medicine, 7(5), 713–720. https://doi.org/10.2217/rme.12.51

How many times has this paper been cited?

26 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Europe PMC (PubMed Central): sign in and open the full text from this page.

Who wrote this paper?

Paul S. Knoepfler.

What is the DOI of this paper?

10.2217/rme.12.51, permanently at https://doi.org/10.2217/rme.12.51. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.